Orlistat is a long-acting and potent specific gastrointestinal lipase inhibitor. It is white or off-white powder at room temperature. It is insoluble in water, soluble in chloroform, and easily soluble in ethanol. It passes through the stomach and small intestine cavity. Intragastric lipase and pancreatic lipase active codon form a covalent bond to inactivate the enzyme. Fat in food cannot be broken down into free fatty acids and monoacylglycerols, so the fat cannot be absorbed and utilized, thereby reducing the body's caloric intake and controlling body weight. This medicine does not need to be absorbed through the body to exert its effects. At the usual dose, fat absorption can be suppressed by 30%. It is rarely absorbed after oral administration and can be metabolized and inactivated in the intestine. The metabolic site is on the wall of the gastrointestinal tract, and the elimination half-life is about 14 to 19 hours. About 97% of this product is excreted with feces, of which 83% is excreted in the original form.
Orlistat can be used clinically for obesity and hyperlipidemia. Under normal circumstances, 120mg can be taken orally once a day, three times a day, and taken within one hour after a meal. After taking the medicine for 2 weeks, the weight may start to decrease. It can be taken continuously for 6 to 12 months. If the dose is increased to more than 400 mg per day, its effect will no longer be enhanced.
Orlistat Orlistat Dosage,Orlistat Weight Loss,Orlistat Function,Orlistat For Weight Loss Jinan Prosperity International Trade Co. Ltd , https://www.jnprosperity.com
Wang Guoqiang expressed his appreciation for the concentrated use of Angelica Pills, a pharmaceutical factory in Lanzhou Foci, to submit the Swedish National Drug Administration's simplified registration application for traditional herbal medicines to the EU. He said that the State Administration of Traditional Chinese Medicine attached great importance to the registration of Chinese medicines in the European Union. Chinese medicine is going global and Chinese medicine is the key. The successful registration of Chinese medicine products in the EU will play a demonstration role in registering in other countries and will be of great significance in promoting Chinese medicine to the world.
Wang Guoqiang emphasized that the next decade is a crucial period for the full implementation of Chinese medicine in the international arena. It is necessary to incorporate the development of Chinese medicine into the national development strategy framework, give full play to the advantages and role of Chinese medicine in foreign cooperation and exchange, and grasp the correct direction of development. As We must continue to conduct in-depth studies of EU drug administration and related rules, fully grasp information, and train a group of talented personnel who are familiar with the rules of international drug administration, have a global perspective, and grasp the development status of the Chinese medicine industry, and clearly understand that Chinese medicine products enter the EU in the form of drugs. The feasible path is to scientifically determine the main direction of attack and actively explore effective models; it is necessary to further increase investment, continuously improve the safety, efficacy and quality of products, respond to the ever-changing international competition, and make the Chinese medicine industry bigger and stronger; Improve the level of Chinese medicine products, technology, and packaging, prepare fully for the Chinese medicine to enter the world and occupy the world market for a long time, and build a number of famous factories, famous shops, and famous drugs in the world; and further develop the “World Alliance of Chinese Medicine Enterprises†and other cooperation The role of the mechanism to avoid vicious competition.
According to the consensus reached by the participants, the conference issued the “Lanzhou Declaration on the Internationalization of Chinese Medicineâ€, which proposes to promote the modernization and internationalization of Chinese medicines, and to increase the international competitiveness of Chinese medicine products and the international market share. This is our common historical responsibility and glorious mission. It is recommended that domestic Chinese medicine companies actively cooperate with relevant research institutes and establish cooperation with EU herbal research institutes to select a variety of proprietary Chinese medicines with certain representativeness and feasibility, and carry out relevant research on EU specific requirements for the quality research and quality control of herbal medicines. Work to solve the key technical issues of Chinese medicine registration in the EU.
The conference was sponsored by the China Chamber of Commerce for the Import and Export of Medicines and Health Products, the Chinese Medicine Association, the People's Government of Lanzhou, and Lanzhou Foci Pharmaceutical Co., Ltd. (Reporter Zhang Dongfeng)
Business News Agency July 4th The “2011 EU Registration High-Level Meeting on Chinese Medicines†with the theme of “Opportunity, Challenge, and Mission†was held on July 3 in Lanzhou, Gansu, and the conference issued the “Lanzhou Declaration on Internationalization of Chinese Medicineâ€. Vice Minister of Health, Director Wang Guoqiang of the State Administration of Traditional Chinese Medicine, Ministry of Foreign Affairs of the Ministry of Commerce, Heads of WTO and other relevant ministries and industry associations, leaders of Lanzhou Municipal People's Government, experts in Chinese medicine at domestic universities and research institutes, and experts at home and abroad Representatives of Chinese medicine companies attended the meeting. The meeting discussed how to use the European Union to enact traditional herbal medicines to simplify the registration directives and to implement the study of Chinese medicines entering the EU pharmaceutical market as pharmaceuticals, and proposed new ideas and countermeasures for Chinese medicine registration in the EU.